• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers


Drug Metabolism and Pharmacokinetics (DMPK ADME) studies

Analyzing ADME properties of compounds to deliver deliver safe, efficacious drugs

Syngene’s drug metabolism and pharmacokinetics (DMPK) teams are well-positioned to provide accurate data and insightful analysis of a drug’s absorption, distribution, metabolism, and excretion (ADME) properties, to help clients shortlist compounds with a high chance of success in later stages of drug development. By conducting the right DMPK ADME studies, we help reduce compound failure, identify compounds with optimal safety profiles, and minimize drug-drug interactions (DDI) in later stages.


Syngene offers a comprehensive suite of DMPK studies, including in vitro ADME and in vivo Pharmacokinetics (PK) studies, that cover both the drug discovery and early drug development phases. Our capabilities include developing class-leading customized assays and implementing a range of protocols as specified by clients.

Through formulation development studies on the characteristics and biological activity of a compound, we help clients make decisions on a drug’s delivery system using attributes such as solubility, self-emulsification, and dosage form. Our well-defined bioanalytical qualification process to quantitatively measure active drugs is shown below.

Why Syngene

Syngene’s scientists are experts in driving cost-effective, reproducible and high-quality data for drug discovery and development programs. The team handles compound dispatch to data upload in 10 calendar days with more than 95% adherence to turnaround time.

Our state-of-the-art infrastructure includes automated solutions, such as ultra-performance liquid chromatography (UPLC) and time-of-flight (Tof) mass spectrometry, which enable rapid processing of bioanalytical data for fast-tracking of drug discovery projects.

Our in vitro ADME and in vivo Pharmacokinetics (PK) studies can be accessed as a stand-alone project (i.e., fee-based or service-based model) or as part of a larger integrated drug discovery (IDD) program.

Development of bioanalytical methods to support bioavailability and pharmacokinetics studies.

  • HPLC -UV and LC-MS/MS based methods
  • Development of efficient extraction procedures (protein precipitation, liquid- liquid extraction, solid-phase extraction)
  • Development of analytical methods in presence of different matrices

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details